>
Japan's railgun takes the sting out of China's hypersonics
After Indonesia, Nepal -- is the Philippines next to erupt?
US plotting dollar 'rug pull' with crypto, gold and lies
Greg Reese: Forensic Study Finds Christchurch Mosque Shooting in New Zealand was Staged
ORNL tackles control challenges of nuclear rocket engines
Tesla Megapack Keynote LIVE - TESLA is Making Transformers !!
Methylene chloride (CH2Cl?) and acetone (C?H?O) create a powerful paint remover...
Engineer Builds His Own X-Ray After Hospital Charges Him $69K
Researchers create 2D nanomaterials with up to nine metals for extreme conditions
The Evolution of Electric Motors: From Bulky to Lightweight, Efficient Powerhouses
3D-Printing 'Glue Gun' Can Repair Bone Fractures During Surgery Filling-in the Gaps Around..
Kevlar-like EV battery material dissolves after use to recycle itself
Laser connects plane and satellite in breakthrough air-to-space link
Lucid Motors' World-Leading Electric Powertrain Breakdown with Emad Dlala and Eric Bach
Total color blindness, or achromatopsia, is generally an inherited disease caused by mutations in one of six different genes, with the majority of cases involving variants in either the CNGA3 or CNGB3 genes. The new gene therapy being trialed focuses on correcting a defect in the CNGA3 gene.
The treatment is somewhat similar to one of the first FDA-approved gene therapies, for vision loss, called Luxturna. These treatments attach a healthy functioning gene to a genetically modified harmless virus. The treatment is injected into a patient's eye and hopefully the correctly functioning gene begins producing whatever protein was previously missing, helping cure the condition caused by the defective gene.